Watanabe Yoshifumi, Nakaba Hiroyuki, Taniguchi Eiji, Kikkawa Hiroyuki, Tamagawa Hiroshi, Sasaki Masaru, Kitayama Toshiaki, Doi Yoshinori, Oguchi Yoshirou
Dept. of Surgery, Otemae Hospital.
Gan To Kagaku Ryoho. 2014 Nov;41(12):2110-2.
We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib. A 74-year-old man underwent hepatectomy for a huge hepatocellular carcinoma, measuring 19 × 13 cm. Multiple intrahepatic HCCs that recurred 5 months post-surgery were treated with TACE. After 3 cycles of TACE, however, sorafenib was administered to treat progressive disease. Six months after sorafenib treatment, TACE combined with sorafenib was administered for treatment of refractory intrahepatic lesions. Following further disease progression, TACE was replaced by up to 11 rounds of HAIC. We report successfully treatment of refractory metastatic HCC with sorafenib for more than 30 months along with a review of the literature.
我们报告了一例转移性肝细胞癌(HCC)患者的长期生存情况,该患者通过经导管动脉化疗栓塞术(TACE)/肝动脉灌注化疗(HAIC)联合长期使用索拉非尼成功治疗。一名74岁男性因巨大肝细胞癌(大小为19×13 cm)接受了肝切除术。术后5个月复发的多个肝内HCC通过TACE治疗。然而,在3个周期的TACE治疗后,给予索拉非尼治疗疾病进展。索拉非尼治疗6个月后,TACE联合索拉非尼用于治疗难治性肝内病变。在疾病进一步进展后,TACE被多达11轮的HAIC取代。我们报告了索拉非尼成功治疗难治性转移性HCC超过30个月的情况,并对文献进行了综述。